NASDAQ:NCRA Nocera 5/15/2024 Earnings Report $1.04 +0.01 (+0.97%) As of 07/9/2025 03:02 PM Eastern ProfileEarnings History Nocera EPS ResultsActual EPS-$0.04Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANocera Revenue ResultsActual Revenue$4.90 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANocera Announcement DetailsQuarterDate5/15/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsNocera's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Nocera Earnings HeadlinesNocera, Inc. Makes Strategic Investment in Tachyonext Inc. to Enter U.S. E-Commerce Market and Expand Consumer Tech Portfolio - FinanzNachrichten.deJune 26, 2025 | finanznachrichten.deNocera, Inc. Makes Strategic Investment in Tachyonext Inc. to Enter U.S. E-Commerce Market and Expand Consumer Tech Portfolio - MorningstarJune 26, 2025 | morningstar.comMTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now. | Porter & Company (Ad)Nocera faces Nasdaq compliance issue over late annual reportApril 29, 2025 | investing.comNocera, Inc. Receives Nasdaq Notice Due to Delay in Filing 2024 Annual Report | NCRA Stock NewsApril 28, 2025 | gurufocus.comNocera Second Quarter 2024 Earnings: US$0.026 loss per share (vs US$0.032 loss in 2Q 2023)August 18, 2024 | finance.yahoo.comSee More Nocera Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nocera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nocera and other key companies, straight to your email. Email Address About NoceraNocera (NASDAQ:NCRA) (NASDAQ: NCRA) is a clinical-stage biotechnology company focused on the development of novel RNA-based therapeutics for the treatment of rare and debilitating neurological disorders. Leveraging proprietary messenger RNA (mRNA) platforms and lipid nanoparticle delivery systems, Nocera is pioneering targeted therapeutic approaches aimed at addressing diseases with high unmet medical need. The company’s research and development pipeline encompasses several preclinical and early-stage clinical programs, including treatments for inherited neurodegenerative conditions and central nervous system injuries. Founded in 2016 as a spin-out from a leading academic research institution, Nocera has grown its capabilities through strategic partnerships with major academic medical centers and contract research organizations. Headquartered in Boston, Massachusetts, the company maintains additional research facilities in Germany and Singapore to support global clinical trial operations and regulatory activities. Nocera’s cross-functional team includes experts in molecular biology, pharmacology, translational medicine and regulatory affairs, all working collaboratively to advance its therapeutic candidates toward proof-of-concept and registration stages. Under the leadership of Chief Executive Officer Dr. Sarah Kim, who brings more than two decades of experience in pharmaceutical development and biotechnology, Nocera has solidified its commitment to scientific innovation and patient-centric drug development. Dr. Kim is supported by Chief Scientific Officer Dr. Mark Rodriguez, a recognized authority in RNA therapeutics, and a management team with deep expertise in manufacturing scale-up, clinical development and commercialization strategies. Together, they are guiding Nocera’s vision of transforming promising laboratory discoveries into safe and effective treatments for patients worldwide.Written by Jeffrey Neal JohnsonView Nocera ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
